Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02825966
Recruitment Status : Completed
First Posted : July 7, 2016
Results First Posted : December 2, 2020
Last Update Posted : December 2, 2020
Sponsor:
Information provided by (Responsible Party):
Zoll Medical Corporation

Brief Summary:
A prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). These data will be compared with the heart sounds data recorded by an FDA-cleared device AUDICOR AM device.

Condition or disease Intervention/treatment Phase
Heart Failure Device: AUDICOR then LifeVest then AUDICOR Not Applicable

Detailed Description:

To conduct a prospective, validation study to evaluate the data accuracy of heart sounds recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). To show equivalence, these data will be compared with the heart sounds data recorded by an FDA-cleared AUDCIOR AM device .

The study will enroll a minimum of 27 and a maximum of 35 subjects.

Participants will be adult patients (age ≥ 18 years) with at least seven patients over the age of 40 years. In addition, at least five patients with a history of heart failure will be included.

First, participants will wear the AUDICOR-AM device for 15 minutes while sitting quietly. Then, the AUDICOR device will be removed and the participants will wear the WCD for 15 minutes while sitting quietly. Next, while wearing the WCD, participants will perform various activities of daily living, including at least 6 hours of overnight wear. Finally, the WCD will be removed and the participants will wear the AUDICOR again for 15 minutes while sitting quietly.

This is a single center, prospective, observational study. This is a non-significant risk device study as all biological study parameters will be measured noninvasively with the WCD defibrillation capability disabled. In addition, the study device will not be used as a replacement for regularly prescribed therapies or diagnostics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Each subject first wears the AUDICOR-AM device for 15 minutes while sitting. Then the AUDICOR device is removed and the subject wears the WCD for 12-16 hours. After the WCD wear period, the WCD device is removed and the subject wears the AUDICOR device again for 15 minutes.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD): Study Protocol
Study Start Date : February 2016
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Arm Intervention/treatment
AUDICOR then LifeVest then AUDICOR
First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
Device: AUDICOR then LifeVest then AUDICOR
Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.




Primary Outcome Measures :
  1. To Establish Equivalence Between the Heart Sounds Data Recorded by the LifeVest and FDA-cleared AUDICOR AM System. [ Time Frame: 15 minutes of sitting for each group of measurements (Audicor device, then LifeVest, then Audicor device again). ]
    Equivalence of the LifeVest device to the AUDICOR device was established by comparing the electromechanical activation time (EMAT) data of each device, collected during quiet sitting. The outcome was reported as the difference in EMAT measured by the LifeVest and AUDICOR device.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).
  • Included in this group are at least five healthy subjects with a self-reported history of heart failure.
  • The subject must be 18 years of age or older on the day of screening, with at least 7 subjects 40 years of age or older on the day of screening.

Exclusion Criteria:

  • Mental, visual, physical, literacy, and auditory limitations that prevent interaction with the WCD equipment.
  • Any acute medical conditions that prevent the following maneuvers: lying on back, lying on the right and left side, standing, sitting, and/ or leaning forward when sitting.
  • Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs, and/or chest pain
  • Employees or family members of the sponsor.
  • Unable or unwilling to provide written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02825966


Locations
Layout table for location information
United States, Ohio
MedPace Phase 1 Clinic
Cincinnati, Ohio, United States, 45227
Sponsors and Collaborators
Zoll Medical Corporation
Investigators
Layout table for investigator information
Study Director: Steve Szymkiewicz, MD VP Medical Affairs
  Study Documents (Full-Text)

Documents provided by Zoll Medical Corporation:
Layout table for additonal information
Responsible Party: Zoll Medical Corporation
ClinicalTrials.gov Identifier: NCT02825966    
Other Study ID Numbers: 90D0153
First Posted: July 7, 2016    Key Record Dates
Results First Posted: December 2, 2020
Last Update Posted: December 2, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases